Key Highlights

  • Consensus EPS of 0.16 compares with diluted EPS of 0.14 reported for the second quarter, against 0.15 a year earlier.
  • Management raised full-year normalized FFO guidance to USD 3.85 to USD 3.90 per share, from the prior range.
  • Investment volume guidance rose to USD 4.5 billion for 2026 from USD 3 billion, focused on senior housing acquisitions.
  • Disposition and loan repayment guidance rose to USD 700 million for the full year, focused on nonstrategic assets.

Ventas (NYSE:VTR) reports third-quarter results on Tuesday, Oct. 27, after the market closes. Consensus stands at EPS of 0.16 on revenue of USD 1.77 billion, and the company has a market capitalization of USD 45.84 billion.

Ventas is a REIT with senior housing, outpatient medical and triple-net portfolios. In the second quarter, it reported revenues of USD 1,729,614 thousand against USD 1,420,893 thousand and net income of USD 72,222 thousand against USD 71,462 thousand.

Estimates Against Company Guidance

The revenue estimate of USD 1.77 billion is above the USD 1,729,614 thousand reported for the second quarter. The EPS estimate of 0.16 is above the diluted EPS of 0.14 reported, which compared with 0.15 a year earlier.

Management reported normalized FFO of USD 0.97 per share, up 9%. Full-year normalized FFO guidance was raised to USD 3.85 to USD 3.90 per share, an 8% to 10% growth rate that management tied primarily to higher investment volume.

What Management Guided and What It Left Open

Management put numbers on the plan. Investment volume guidance rose to USD 4.5 billion, with USD 3.4 billion completed across 27 transactions year to date, at an average year one yield of 6.6% and an average price of USD 358,000 per unit. Disposition and loan repayment guidance rose to USD 700 million.

Management said the timing and slope of the key selling season, from May through September, is the main determinant of full-year results. It also said higher interest rates and a higher share price offset USD 0.01 of the guidance change, and it gave no figure beyond the stated range.

Management said it anticipates triple-net same-store cash NOI growth of 3% to accelerate in the second half, without a quantified range.

Changes in the Latest Results

Total same-property NOI rose 10%, SHOP same-store NOI rose 16%, and U.S. SHOP NOI rose 18%. Same-store occupancy rose 300 basis points, SHOP NOI margin was 31%, up 210 basis points, and RevPOR rose 5% against a 5% rise in operating expenses.

OM&R same-store cash NOI rose 5%, with tenant retention of 88% in outpatient medical. The filing ties SHOP growth to higher average occupancy, revenue per occupied room, acquisitions and conversions of communities from the triple-net segment.

Interest expense was USD 160,034 thousand against USD 150,298 thousand. Income before taxes was USD 54,240 thousand against USD 42,658 thousand, and the filing cites a tax benefit from reversing valuation allowances.

Net debt to EBITDA was 4.7x, liquidity was USD 4.9 billion, and equity raised year to date was USD 4.2 billion, including USD 1.6 billion in unsettled forward sales.

Markers for the Release

Normalized FFO against the USD 3.85 to USD 3.90 range and revenue against USD 1.77 billion are the first comparisons. Other markers are SHOP occupancy and margin, investment volume against USD 4.5 billion and the selling season.